Valneva’s revenue climbs 9% despite financial hurdles and vaccine trials ahead
Valneva has reported steady growth in the first nine months of 2025, with revenue climbing by nearly 9% to €127 million. The increase comes from strong product sales, though the company still faces financial challenges. Investors are now watching closely as its Lyme disease vaccine candidate, VLA15, enters a critical phase of testing.
The company’s financial position shows both progress and setbacks. While revenue rose to €127 million, a net loss of €65.2 million was recorded—partly due to the absence of a €90 million windfall from 2024, when Valneva sold a Priority Review Voucher. Still, the firm has cut its operating cash burn by over 60%, dropping from €76.7 million to €28.4 million compared to the same period last year.
The next few months will be decisive for Valneva. Results from the VLA15 trial could shape the company’s future, while its improved cash position and refinancing offer some financial security. With a confirmed revenue target and a unique vaccine in development, the firm remains focused on turning its prospects around.
